University of Crete (UOC)
Study of the alterations of myeloid-derived suppressor cells in patients with bone marrow failure syndromes and correlation with clinical and epidemiological characteristics, quality of life, and disease outcomes, including the occurrence of severe respiratory tract infections
Abstract
dc:descriptionCytopenia constitutes low peripheral blood (PB) cell counts of one or more of the haematopoietic lineages and can be of central origin, i.e. due to less production and/or abnormal differentiation of the precursor cells in the bone marrow (BM), or peripheral origin, i.e. due to destruction of the mature cells in the periphery. Bone marrow failure syndromes (BMFS) constitute a heterogeneous group of disorders of the haematopoietic precursors and the BM microenvironment that is characterised by cytopenias due to decreased production of one or more of the haematopoietic lineages and varying degrees of probability of progression to acute myeloid leukaemia. Chronic idiopathic neutropenia (CIN), which is one of the conditions included in the term BMFS, is characterised by the persistent and unexplained reduction of PB absolute neutrophil counts. The pathogenesis of CIN has been associated with increased apoptosis of the granulocytic progenitor cells due to an inflammatory BM microenvironment consisting of activated T lymphocytes, proinflammatory monocytes, and proapoptotic cytokines.Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells, deviating from the standard differentiation pathway during (aberrant) myelopoiesis, that display immunomodulatory properties mainly by suppressing T-cell responses and are increased in chronic inflammation, autoimmune diseases and cancer. This study aimed at investigating the number and functional characteristics of the subpopulations of MDSCs, i.e. polymorphonuclear (PMN-) MDSCs and mononuclear (M-) MDSCs, in patients suffering from BMFS, especially patients with myelodysplastic neoplasms (MDS), aplastic anaemia (AA), and CIN, and correlate them with disease outcomes. The literature was systematically searched and a number of studies investigating the number and functionality of MDSCs in BMFS were found. Based on the systematic synthesis of the literature, MDSCs seemed to be increased in higher-risk MDS and unaffected or in smaller numbers in lower-risk MDS. The high numbers of MDSCs were correlated with poor outcomes for the patients. On the other hand, MDSCs were found to be decreased in patients with AA, while their functionality was also impaired. There were no studies, except ours, found regarding MDSCs in neutropenia of central origin and, thus, in the present study we explored for the first time the possible involvement of MDSCs in the pathophysiology of such a condition by investigating their number, functional characteristics, and transcriptome profile in a group of CIN patients and age- and sex-matched healthy controls (HCs). We found that CIN patients display significantly lower proportions of MDSCs in both the PB and BM mononuclear cell fractions compared to HCs. The MDSCs from CIN patients and HCs could suppress T cells ex vivo, but the patient MDSCs displayed differentiated transcriptome profile, compared to HCs, suggesting possible functional abnormalities of the cells in vivo. Specifically, patient MDSCs highly expressed genes related to T-cell activation/responses, while they expressed at a lower level, genes related to innate immunity functions. Genes important for cell viability, such as repair of DNA damage and response to toxic substances, are also expressed at a lower level. Based on our results, we suggest that the lower numbers and altered properties of MDSCs in CIN may contribute to the pathophysiology of the disease by sustaining/inducing the immune dysregulation. In conclusion, MDSCs are altered in numbers and functionality in patients with BMFS and these alterations may be correlated with poor disease outcomes. We expect that the results of our study will highlight the role of MDSCs as new therapeutic target for these patients as well as new biomarkers for disease activity and response to treatment.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Bizymi, Nikoleta
- Μπιζύμη, Νικολέτα
Subjects
dc:subject × 20- Μυελικά κατασταλτικά κύτταρα
- Φλεγμονή
- Λοίμωξη
- Καρκίνος
- Σύνδρομα μυελικής ανεπάρκειας
- Ανοσία
- Βιοδείκτες
- Myeloid-derived suppressor cells
- Inflammation
- Infection
- Cancer
- Bone marrow failure syndromes
- Immunity
- Biomarkers
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ανοσολογία
- Basic Medicine
- Medical and Health Sciences
- Immunology
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/57862